Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 43Cyclophosphamide 41fludarabine phosphate 24Filgrastim 19fludarabine 16Lenalidomide 15Bendamustine Hydrochloride 15Peripheral Blood Stem Cell Transplantation 14Bortezomib 13Etoposide 11venetoclax 10ibrutinib 10Radiotherapy 10Biopsy 10aldesleukin 9Vincristine 9Prednisone 9Magnetic Resonance Spectroscopy 9Vorinostat 8Specimen Handling 8Cytarabine 8Cyclosporine 8pembrolizumab 7obinutuzumab 7Paclitaxel 7Gemcitabine 7Flow Cytometry 7tanespimycin 6Tacrolimus 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Follicular × Erythromycin × Clear all
NCT02381080 2017-06-26

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

Janssen Research & Development, LLC

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡